Skip to content

The Challenge of Clostridium difficile and Antimicrobial-Resistant Gram-negative Infections: Opportunities to Re-evaluate Current Management Approaches

Activity Post Test and Evaluation Form

Post Test

Please note that to receive credit you must achieve a score of at least 70%.

Pharmacists: The information that you participated will be uploaded to CPE Monitor and you will be able to access your credits from the profile you set up with NABP. For more information, please visit http://www.nabp.net/.
1.All of the following events in C. difficile infection pathophysiology increase the risk of symptomatic infection except:
2.Which of the following has demonstrated an advantage in reducing recurrent CDI infections when compared to vancomycin?
3.Which of the following treatment options would be most effective in reducing the risk of recurrent infection in a 68-year-old woman with 4 episodes of CDI in the past 3 months?
4.Which of the following was identified by the World Health Organization as a critical priority pathogen?
5.Ceftolozane-tazobactam and ceftazidime-avibactam both exhibit effective in vitro activity against:
6.A 58-year-old man is admitted to the ICU following a motor vehicle accident and is immediately intubated. After 3 days, he develops fever and a chest radiograph reveals pulmonary infiltrates. A BAL is performed and he is given empiric piperacillin-tazobactam and vancomycin. After 36 hours, he has not improved and culture reveals ESBL-producing K. pneumoniae. In addition to discontinuing vancomycin, you decide to: